DOI: 10.1101/19009092Nov 2, 2019Paper

Predicting Clinical Dementia Rating Using Blood RNA Levels

MedRxiv : the Preprint Server for Health Sciences
J. B. Miller, John SK Kauwe


INTRODUCTION: The Clinical Dementia Rating (CDR) is commonly used to assess cognitive decline in Alzheimer's disease patients. METHODS: We divided 741 participants with blood microarray data in the Alzheimer's Disease Neuroimaging Initiative (ADNI) into three groups based on their most recent CDR assessment: cognitive normal (CDR=0), mild dementia (CDR=0.5), and probable AD (CDR[≥]1.0). We then used machine learning to predict cognitive status using only blood RNA levels. RESULTS: One chloride intracellular channel 1 (CLIC1) probe was significant. By combining nonsignificant probes with p-values less than 0.1, we averaged 87.87 (s = 1.02)% predictive accuracy in classifying the three groups, compared to a 55.46% baseline for this study. DISCUSSION: We identified one significant probe in CLIC1. However, CLIC1 levels alone were not sufficient to determine dementia status. We propose that combining individually suggestive, but nonsignificant, blood RNA levels can significantly improve diagnostic accuracy.

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Alzheimer's Disease: Microglia (Preprints)

Microglial proliferation and activation, as well as its concentration around amyloid plaques, is a prominent feature of Alzheimer’s disease. Here is the latest research on microglia and Alzheimer’s disease.